Payer Briefs: Express Scripts Pricing Pilot; HHS Risk Adjustment; Value Frameworks
This article was originally published in The Pink Sheet Daily
Indication-based pricing experiment by Express Scripts gets off to a quiet start; HHS makes progress on factoring Rx spending in its risk adjustment calculations for ACA plans and the National Pharmaceutical Council releases recommended standards for drug value assessments.
You may also be interested in...
Express Scripts' plan to reimburse at levels according to value of specific indications in inflammatory diseases will create more space for new entrants with proven value.
The most detailed US reporting requirements regarding prescription drug costs and coverage will target medicines reimbursed under the retail pharmacy benefit.
US government is paying Merck & Co. around $181 more per course of treatment for its oral antiviral for COVID-19, molnupiravir, than it is to Pfizer for its competing drug.